Correlation Between XSpray Pharma and Senzime AB
Can any of the company-specific risk be diversified away by investing in both XSpray Pharma and Senzime AB at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining XSpray Pharma and Senzime AB into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between XSpray Pharma AB and Senzime AB, you can compare the effects of market volatilities on XSpray Pharma and Senzime AB and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in XSpray Pharma with a short position of Senzime AB. Check out your portfolio center. Please also check ongoing floating volatility patterns of XSpray Pharma and Senzime AB.
Diversification Opportunities for XSpray Pharma and Senzime AB
0.44 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between XSpray and Senzime is 0.44. Overlapping area represents the amount of risk that can be diversified away by holding XSpray Pharma AB and Senzime AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Senzime AB and XSpray Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on XSpray Pharma AB are associated (or correlated) with Senzime AB. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Senzime AB has no effect on the direction of XSpray Pharma i.e., XSpray Pharma and Senzime AB go up and down completely randomly.
Pair Corralation between XSpray Pharma and Senzime AB
Assuming the 90 days trading horizon XSpray Pharma AB is expected to generate 1.63 times more return on investment than Senzime AB. However, XSpray Pharma is 1.63 times more volatile than Senzime AB. It trades about -0.03 of its potential returns per unit of risk. Senzime AB is currently generating about -0.17 per unit of risk. If you would invest 4,375 in XSpray Pharma AB on October 8, 2024 and sell it today you would lose (75.00) from holding XSpray Pharma AB or give up 1.71% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Weak |
Accuracy | 100.0% |
Values | Daily Returns |
XSpray Pharma AB vs. Senzime AB
Performance |
Timeline |
XSpray Pharma AB |
Senzime AB |
XSpray Pharma and Senzime AB Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with XSpray Pharma and Senzime AB
The main advantage of trading using opposite XSpray Pharma and Senzime AB positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if XSpray Pharma position performs unexpectedly, Senzime AB can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Senzime AB will offset losses from the drop in Senzime AB's long position.XSpray Pharma vs. Xbrane Biopharma AB | XSpray Pharma vs. Hansa Biopharma AB | XSpray Pharma vs. Cantargia AB | XSpray Pharma vs. Vicore Pharma Holding |
Senzime AB vs. BioArctic AB | Senzime AB vs. Oncopeptides AB | Senzime AB vs. Hansa Biopharma AB | Senzime AB vs. Swedish Orphan Biovitrum |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Complementary Tools
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |